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Background
Plans are in the pipeline to commence field trials to deter-
mine the efficacy of HIV vaccines amongst the Nigerian
populace. This study was conducted to assess the willing-
ness to participate as subjects in HIV vaccine trials among
young male traders in Ibadan, Nigeria.
Materials and methods
Self administered questionnaires were completed by 247
respondents with age ranging from 13 to 29 years. The
questions were in Pidgin English which is an adulterated
form of English language widely spoken among the
respondents. SPSS version 10 data editor was used to ana-
lyze data. Univariate odds ratios and 95% confidence
intervals (95 % CI) were used to evaluate the correlates of
willingness to participate (WTP) in vaccine trials.
Results
35% of the respondents reported that they will be willing
to join HIV vaccine trials. Greater willingness was associ-
ated with prior sexual experience (OR = 1.23, 95% CI:
1.12–1.53), involvement in high risk sexual behaviour
(OR = 1.35, 95% CI: 1.05–1.62), higher levels of aware-
ness about HIV/AIDS (OR = 1.37, 95% CI: 1.14–1.45)
and tangible incentives (OR = 1.39, 95% CI: 1.02–1.42).
Decreased WTP was associated with concerns about phys-
ical harm (OR = 0.62, 95% CI: 0.21–0.54), social stigma-
tization (OR = 0.71, 95% CI: 0.42–0.68), use of parenteral
route for vaccine administration (OR = 0.78, 95% CI:
0.53–0.76) and multiple doses of vaccines (OR = 0.81,
95% CI: 0.46–0.63).
Conclusion
The level of WTP recorded indicates that much work still
needs to be done in the area of educating potential sub-
jects in HIV vaccine trials about the safety of these vac-
cines. Incentives for would-be subjects should also be a
part of the planning to encourage greater participation in
these trials.
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